PDCD1 and neoplasm: Our work demonstrates that a combination of anti-TGF-β and anti-PD-1 significantly inhibits the growth of EGFR-TKI resistant tumor cells both in vitro and in vivo, highlighting the potential of combination therapy for patients after failure of EGFR-TKI treatment.